Ezetimibe and Insulin Resistance

Curr Vasc Pharmacol. 2022;20(4):315-317. doi: 10.2174/1570161120666220301140528.

Authors

Djordje S Popovic^{1

2}, Stella Papachristou³, Edita Stokic^{1

2}, Nikolaos Papanas³

Affiliations

¹ Clinic for Endocrinology, Diabetes and Metabolic Disorders, Clinical Centre of Vojvodina, Novi Sad, Serbia.
² Medical Faculty, University of Novi Sad, Novi Sad, Serbia.
³ Diabetes Centre, Second Department of Internal Medicine, Democritus University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece.

PMID: 35232351
DOI: 10.2174/1570161120666220301140528

No abstract available

Publication types

Editorial

MeSH terms

Anticholesteremic Agents* / adverse effects
Ezetimibe / adverse effects
Humans
Hypercholesterolemia*
Insulin Resistance*

Substances

Ezetimibe
Anticholesteremic Agents